Bioanalytical study by HPLC for Quantification of Drug in Plasma Blood Concentration
DOI:
https://doi.org/10.22270/ajprd.v13i6.1670Abstract
Bioanalytical quantification plays a vital role in pharmaceutical, clinical, and toxicological biological matrices such as plasma, serum, urine, and tissues. These measurements support the evaluation of pharmacokinetic (ADME) behavior, therapeutic effectiveness, and drug safety. However, biological matrices contain numerous endogenous substances that can introduce matrix effects, affecting extraction efficiency, chromatographic separation, and detector response, thereby reducing accuracy and sensitivity. High-Performance Liquid Chromatography (HPLC) is a highly reliable analytical technique widely used for the separation and quantification of analytes in complex samples due to its superior selectivity, precision, and reproducibility. Method development in HPLC involves careful selection of stationary and mobile phases, optimization of chromatographic conditions, and appropriate detection strategies such as UV, fluorescence, and LC–MS/MS. Robust sample preparation methods—including protein precipitation, liquid–liquid extraction, and solid-phase extraction—are essential to minimize matrix interference and enhance analytical performance. Regulatory validation ensures compliance with accuracy, precision, linearity, stability, and selectivity requirements for routine application in bioanalysis. Continuous advancements in UHPLC, hyphenated techniques, automation, and green analytical approaches are further improving throughput, sensitivity, and sustainability. Thus, HPLC-based bioanalytical quantification remains indispensable for drug development, therapeutic drug monitoring, and personalized medicine.
Downloads
References
Singh S, Goyal N, Kadian J. Review on pharmacovigilance. [Journal Name]. 2015;4:266-75. Indian Pharmacopoeia Commission. Pharmacovigilance Programme of India (PvPI) [Internet]. Available from: https://www.ipc.gov.in/PvPI/about.html
Suke SG, Kosta P, Negi H. Role of Pharmacovigilance in India: An overview. Online J Public Health Inform. 2015 Jul 1;7(2):e223. doi: 10.5210/ojphi.v7i2.5595. PMID: 26392851; PMCID: PMC4576445.
Manohar D. Kengar, Kiran K. Patole, Akshay K. Ade, Sumesh M. Kumbhar, Chetan D. Patil, Ashutosh R. Ganjave. Introduction to Pharmacovigilance and Monitoring. Asian J. Pharm. Res. 2019; 9(2): 116-122. doi: 10.5958/2231-5691.2019.00019.4
Rohilla A, Singh N, Kumar V, Sharma MK, Dahiya A, Kushnoor A. Pharmacovigilance: needs and objectives. J Adv Pharm Educ Res. 2012;4:201-5.
Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: A review with particular focus on Africa. Br J Clin Pharmacol. 2023 Feb;89(2):491-509. doi: 10.1111/bcp.15193. Epub 2022 Feb 9. PMID: 34937122.
Kunal S Rewale, Ajit B Tuwar, Dr. Megha T Salve. A brief review on pharmacovigilance. Int J Pharm Sci Drug Anal 2024;4(1):09-16.
Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. Indian J Pharmacol. 2019 Nov- Dec;51(6):373-376. doi: 10.4103/ijp.IJP_814_19. Epub 2020 Jan 16. PMID: 32029958; PMCID: PMC6984023.
Trifirò G, Crisafulli S. A new era of pharmacovigilance: future challenges and opportunities. Frontiers in Drug Safety and Regulation. 2022 Feb 25;2:866898.
Global Pharmacovigilance. Pharmacovigilance process. Available from: https://globalpharmacovigilance.com/pharmacovigilance-process. Accessed on: 30 Mar 2025.
Pharmacy Infoline. History and development of pharmacovigilance. Available from: https://pharmacyinfoline.com/history-and-development-of-pharmacovigilance/. Accessed on: 30 Mar 2025.
Fornasier G, Francescon S, Leone R, Baldo P. An historical overview over Pharmacovigilance. Int J Clin Pharm. 2018 Aug;40(4):744-747. doi: 10.1007/s11096-018-0657-1. Epub 2018 Jun 15. PMID: 29948743; PMCID: PMC6132952.
Career in Pharma. Pharmacovigilance: history & future in India. Available from: https://careerinpharma.com/pharmacovigilance-history-future-in-india/. Accessed on: 30 Mar 2025.
Pan American Health Organization. Pharmacovigilance [Internet]. Washington, D.C.: PAHO;[cited 2025 Mar 27].Available from https://www.paho.org/en/topics/pharmacovigilance
Amale PN, Deshpande SA, Nakhate YD, Arsod NA. Pharmacovigilance process in India: An overview. J Pharmacovigil. 2018;6(2):259.
Bhangale R, Vaity S, Kulkarni N. A day in the life of a pharmacovigilance case processor. Perspect Clin Res. 2017 Oct- Dec;8(4):192-195. doi: 10.4103/picr.PICR_120_17. PMID: 29109938; PMCID: PMC56542200
Pharmalex. Signal detection: the complete guide. Available from: https://www.pharmalex.com/thought-leadership/blogs/signal-detection-the-complete-guide/. Accessed on: 30 Mar 2025.
Rohilla A, Yadav S. Adverse drug reactions: an overview. Int J Pharmacol Res. 2013;3(1):10-2
Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016 Oct;16(5):481-485. doi: 10.7861/clinmedicine.16-5-481. PMID: 27697815; PMCID: PMC6297296
Pharmalex. Signal detection: the complete guide. Available from: https://www.pharmalex.com/thought-leadership/blogs/signal-detection-the-complete-guide/. Accessed on: 30 Mar 2025.
Types of ICSR in Pharmacovigilance (Cite: Swathi S. Types of ICSR in pharmacovigilance [Internet]. Clini India [cited 2025 Mar 25]. Available from: https://www.cliniindia.com/types-of-icsr-in-pharmacovigilance/.
New Jersey Department of Health. Vaccine Adverse Event Reporting System (VAERS). Available from: https://www.nj.gov/health/cd/vaersindex.shtml. Accessed on: 30 Mar 2025.
Rohilla A, Singh RK, Sharma D, Keshari R, Kushnoor A. Phases of clinical trials: a review. International Journal of Pharmaceutical, Chemical & Biological Sciences. 2013 Jul 1;3(3).
Samala VR, Venkatesh P. Phases of clinical trials: a review. Asian Journal of Hospital Pharmacy. 2022 Jan 24:09-13.
CliniIndia. Understanding US FDA vs EMA vs CDSCO: How do they differ? Available from: https://www.cliniindia.com/understanding-us-fda-vs-ema-vs-cdsco-how-do-they-differ/. Accessed on: 30 Mar 2025.
U.S. Food and Drug Administration. FDA's Adverse Event Reporting System (FAERS). Available from: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/fdas-adverse-event-reporting-system-faers. Accessed on: 30 Mar 2025.
World Health Organisation (WHO). The importance of pharmacovigilance: safety monitoring of medicinal products Geneva WHO; 2002
Hire RC, Kinage PJ, Gaikwad NN. Causality assessment in pharmacovigilance: a step towards quality care. Sch J App Med Sci. 2013;1(5):386-92.
Nagarajan S, Mahapatro G. Meddra Coding in Pharmacovigilance: A comprehensive review of Its role, challenges, and best practices in adverse event reporting and regulatory compliance. International Journal of Pharmaceuticals and Health Care Research. 2024 Nov 19;12(4):389-92
Liu M, Matheny ME, Hu Y, Xu H. Data mining methodologies for pharmacovigilance. ACM SIGKDD Explorations Newsletter. 2012 Dec 10;14(1):35-42
ClinSkill Academy. Data mining techniques in pharmacovigilance. Available from: https://www.clinskillacademy.com/data-mining-techniques-in-pharmacovigilance. Accessed on: 30 Mar 2025.
Biotech. Benefit-risk assessment for regulatory process. Available from: https://biotech.com/2023/03/21/benefit-risk-assessment-for-regulatory-process/. Accessed on: 30 Mar 2025.
Guo, J.J., Pandey, S., Doyle, J., Bian, B., Lis, Y. and Raisch, D.W. (2010), A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group. Value in Health, 13: 657-666. https://doi.org/10.1111/j.1524-4733.2010.00725).
Gordillo-Marañón M, Candore G, López-Fauqued M, Deli KC, Piccolo L, Alcini P, Paternoster-Howe T, Rager I, Ruepp R, van der Elst M. Predicting the submission frequency of periodic safety update reports: development and application of the EURD tool. Front Med (Lausanne). 2024 Feb 8;11:1299190. doi: 10.3389/fmed.2024.1299190. PMID: 38390565; PMCID: PMC10882634
Davis, B., & Southworth, H. (2015). Statistical Analysis of Cumulative Serious Adverse Event Data From Development Safety Update Reports. Therapeutic Innovation & Regulatory Science, 50(2), 188–194. doi:10.1177/2168479015602735)
Central Drugs Standard Control Organization (CDSCO). Pharmacovigilance [Internet]. New Delhi: Ministry of Health and Family Welfare, Government of India; [cited 2025 Mar 29]. Available from: https://cdsco.gov.in/opencms/opencms/en/Pharmacovigilance/
U.S. Food and Drug Administration (FDA). MedWatch: The FDA safety information and adverse event reporting program [Internet]. Silver Spring, MD: FDA; [cited 2025 Mar 29]. Available from: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card: Report a problem with a medicine or medical device [Internet]. London: MHRA; [cited 2025 Mar 29]. Available from: https://yellowcard.mhra.gov.uk/
Health Canada. Adverse reaction reporting – MedEffect Canada [Internet]. Ottawa: Health Canada; [cited 2025 Mar 29]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html
Therapeutic Goods Administration (TGA). Reporting problems [Internet]. Canberra: Department of Health and Aged Care, Australian Government; [cited 2025 Mar 29]. Available from: https://www.tga.gov.au/reporting-problems
European Medicines Agency (EMA). Pharmacovigilance [Internet]. Amsterdam: EMA; [cited 2025 Mar 29]. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance
Pharmaceuticals and Medical Devices Agency (PMDA). PMDA official website [Internet]. Tokyo: PMDA; [cited 2025 Mar 29]. Available from: https://www.pmda.go.jp/
Pharmacovigilance in Post-Marketing Surveillance: Ensuring Drug Safety in LATAM
Singh T. The significance of ecopharmacovigilance in the current environmental situations [Internet]. Int J Pharm Phytopharm Res. [cited 2025 Mar 27]. Available from: https://ijppr.humanjournals.com/wp-content/uploads/2023/02/1.Tanuja-Singh.pdf )
Indian Pharmacopoeia Commission. Guidance document for Materiovigilance Programme of India (MvPI) [Internet]. Ghaziabad: IPC; [cited 2025 Mar 27]. Available from: https://ipc.gov.in/images/Guidance_Document_MvPI.pdf
Finessen Institute. PV Softwares. Available from: https://www.finenessinstitute.com/pv-softwares/. Accessed on: 30 Mar 2025.
Daffodil Software. What is the role of AI in pharmacovigilance? Available from: https://insights.daffodilsw.com/blog/what-is-the-role-of-ai-in-pharmacovigilance. Accessed on: 30 Mar 2025.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Vaishnavi A Shirsath, DR. Kaveri M Nannor, Pallavi k Danke, Rutuja D Khare, Sakshi B Vanjul
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 